Canaccord analyst John Newman raised the firm’s price target on Regeneron to $853 from $750 and keeps a Buy rating on the shares. The analyst raised the firm’s target based on expectations for continued EYLEA growth in 2023, FDA approval for the high dose 8 mg formulation of EYLEA, and upcoming co-stim data in combination with Libtayo.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron price target raised to $756 from $670 at Baird
- Piper ups Regeneron price target to $800, says Q4 report ‘good enough’
- Regeneron Posts Q4 Beat; Shares Rise
- Regeneron announces new $3B share repurchase program
- Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results